...
kpti-img

Karyopharm Therapeutics Inc, Common Stock

KPTI

NSQ

$0.7949

-$0.02

(-2.47%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$101.51M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.50M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.15
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.62 L
$1.95 H
$0.7949

About Karyopharm Therapeutics Inc, Common Stock

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKPTISectorS&P500
1-Week Return-6.76%-0.09%0.83%
1-Month Return-14.8%0.03%5.98%
3-Month Return11.53%-6.26%9.65%
6-Month Return-14.25%1.16%14.29%
1-Year Return-9.16%11.16%32.26%
3-Year Return-88.17%11.98%31.61%
5-Year Return-95.59%47.19%94.03%
10-Year Return-98.23%109.06%191.47%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue40.89M108.08M209.82M157.07M146.03M[{"date":"2019-12-31","value":19.49,"profit":true},{"date":"2020-12-31","value":51.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.86,"profit":true},{"date":"2023-12-31","value":69.6,"profit":true}]
Cost of Revenue2.41M2.71M3.40M5.21M4.94M[{"date":"2019-12-31","value":46.17,"profit":true},{"date":"2020-12-31","value":51.89,"profit":true},{"date":"2021-12-31","value":65.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.8,"profit":true}]
Gross Profit38.49M105.38M206.42M151.86M141.09M[{"date":"2019-12-31","value":18.64,"profit":true},{"date":"2020-12-31","value":51.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.57,"profit":true},{"date":"2023-12-31","value":68.35,"profit":true}]
Gross Margin94.11%97.50%98.38%96.68%96.62%[{"date":"2019-12-31","value":95.67,"profit":true},{"date":"2020-12-31","value":99.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.27,"profit":true},{"date":"2023-12-31","value":98.21,"profit":true}]
Operating Expenses227.76M277.23M304.69M294.06M270.63M[{"date":"2019-12-31","value":74.75,"profit":true},{"date":"2020-12-31","value":90.99,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.51,"profit":true},{"date":"2023-12-31","value":88.82,"profit":true}]
Operating Income(189.28M)(171.85M)(98.27M)(142.20M)(129.54M)[{"date":"2019-12-31","value":-18927500000,"profit":false},{"date":"2020-12-31","value":-17185000000,"profit":false},{"date":"2021-12-31","value":-9827100000,"profit":false},{"date":"2022-12-31","value":-14220200000,"profit":false},{"date":"2023-12-31","value":-12953999900,"profit":false}]
Total Non-Operating Income/Expense(20.50M)(48.43M)(51.01M)(45.36M)(26.98M)[{"date":"2019-12-31","value":-2050000000,"profit":false},{"date":"2020-12-31","value":-4843400000,"profit":false},{"date":"2021-12-31","value":-5101300000,"profit":false},{"date":"2022-12-31","value":-4535700000,"profit":false},{"date":"2023-12-31","value":-2697900100,"profit":false}]
Pre-Tax Income(199.55M)(195.96M)(123.82M)(164.92M)(142.78M)[{"date":"2019-12-31","value":-19955000000,"profit":false},{"date":"2020-12-31","value":-19596400000,"profit":false},{"date":"2021-12-31","value":-12382000000,"profit":false},{"date":"2022-12-31","value":-16492200000,"profit":false},{"date":"2023-12-31","value":-14277600000,"profit":false}]
Income Taxes40.00K309.00K268.00K369.00K323.00K[{"date":"2019-12-31","value":10.84,"profit":true},{"date":"2020-12-31","value":83.74,"profit":true},{"date":"2021-12-31","value":72.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.53,"profit":true}]
Income After Taxes(199.59M)(196.27M)(124.09M)(165.29M)(143.10M)[{"date":"2019-12-31","value":-19959000000,"profit":false},{"date":"2020-12-31","value":-19627300000,"profit":false},{"date":"2021-12-31","value":-12408800000,"profit":false},{"date":"2022-12-31","value":-16529100000,"profit":false},{"date":"2023-12-31","value":-14309900000,"profit":false}]
Income From Continuous Operations(199.59M)(196.27M)(124.09M)(165.29M)(139.77M)[{"date":"2019-12-31","value":-19959000000,"profit":false},{"date":"2020-12-31","value":-19627300000,"profit":false},{"date":"2021-12-31","value":-12408800000,"profit":false},{"date":"2022-12-31","value":-16529100000,"profit":false},{"date":"2023-12-31","value":-13976800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(199.59M)(196.27M)(124.09M)(165.29M)(143.10M)[{"date":"2019-12-31","value":-19959000000,"profit":false},{"date":"2020-12-31","value":-19627300000,"profit":false},{"date":"2021-12-31","value":-12408800000,"profit":false},{"date":"2022-12-31","value":-16529100000,"profit":false},{"date":"2023-12-31","value":-14309900000,"profit":false}]
EPS (Diluted)(3.23)(2.73)(1.71)(2.03)(1.25)[{"date":"2019-12-31","value":-323,"profit":false},{"date":"2020-12-31","value":-273,"profit":false},{"date":"2021-12-31","value":-171,"profit":false},{"date":"2022-12-31","value":-203,"profit":false},{"date":"2023-12-31","value":-125,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KPTI
Cash Ratio 2.17
Current Ratio 3.00
Quick Ratio 2.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KPTI
ROA (LTM) -34.27%
ROE (LTM) -891.05%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KPTI
Debt Ratio Lower is generally better. Negative is bad. 1.84
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.84

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KPTI
Trailing PE NM
Forward PE NM
P/S (TTM) 0.67
P/B 12.05
Price/FCF NM
EV/R 1.09
EV/Ebitda NM
PEG NM

FAQs

What is Karyopharm Therapeutics Inc share price today?

Karyopharm Therapeutics Inc (KPTI) share price today is $0.7949

Can Indians buy Karyopharm Therapeutics Inc shares?

Yes, Indians can buy shares of Karyopharm Therapeutics Inc (KPTI) on Vested. To buy Karyopharm Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KPTI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Karyopharm Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Karyopharm Therapeutics Inc (KPTI) via the Vested app. You can start investing in Karyopharm Therapeutics Inc (KPTI) with a minimum investment of $1.

How to invest in Karyopharm Therapeutics Inc shares from India?

You can invest in shares of Karyopharm Therapeutics Inc (KPTI) via Vested in three simple steps:

  • Click on Sign Up or Invest in KPTI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Karyopharm Therapeutics Inc shares
What is Karyopharm Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Karyopharm Therapeutics Inc (KPTI) is $1.95. The 52-week low price of Karyopharm Therapeutics Inc (KPTI) is $0.62.

What is Karyopharm Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Karyopharm Therapeutics Inc (KPTI) is

What is Karyopharm Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Karyopharm Therapeutics Inc (KPTI) is 12.05

What is Karyopharm Therapeutics Inc dividend yield?

The dividend yield of Karyopharm Therapeutics Inc (KPTI) is 0.00%

What is the Market Cap of Karyopharm Therapeutics Inc?

The market capitalization of Karyopharm Therapeutics Inc (KPTI) is $101.51M

What is Karyopharm Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Karyopharm Therapeutics Inc is KPTI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top